We are offering grants for researchers investigating novel drug targets in the fields of Oncology, Gynecology, Cardiology and Hematology to promote innovative therapeutic ideas from basic research into novel drugs.
We provide financial support to test your hypothesis, start or extend your present research activities.
Focus on oncogenic signaling.
Focus on novel treatment options for endometriosis (incl. adenomyosis uteri/endometriosis interna), uterine fibroids (uterine leiomyoma) and polycystic ovary syndrome (PCOS).
Focus on novel approaches to the care of chronic and/or acute pulmonary hypertension & adjacent lung indications, atrial fibrillation, heart failure, acute coronary syndrome, ischemic stroke, peripheral arterial occlusive disease, acute lung injury/adult respiratory distress syndrome, cardiorenal syndrome and including kidney and lung diseases.
Focus on novel, innovative targets for hemophilia.
The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein.
There are two types of grants, that will be allocated by Bayer depending on the target, the scientific data provided and the maturity of the proposal.
Support grants (€ 5,000 - €10,000)*
For druggable targets that are at a very early stage of discovery.
Focus grants (€ 10,000 - €125,000)*
For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug discovery process.
* The size of the individual grant will depend on the target specifics and the phase of development and validation.
Within Bayer´s Compound Collection, we may have chemical probes to support your target validation efforts. Please indicate in your application which requirements potential tool compounds should fulfill.
Bayer’s Antibody Discovery unit may be able to support your target validation work. Recombinant antibody engineering technology can be used to generate suitable antibodies for your validation needs.
Please specify which in vitro/in vivo models you´ll be using and the requirements potential tool antibodies should fulfill.
We can offer access to different technologies to assist in your target validation, e.g. gene expression profiling or other state-of-the-art research technologies. Please detail your research interest for the technology platforms in the online submission.
Successful projects supported by the grant may lead to further collaboration.
Grant applications can only be submitted via the online submission platform ScholarOne™.
As first step, you’ll have to create an account in the Grants4Targets Submission central.
You’ll need to submit an abstract describing your idea and target, its characteristics and a separate description of its therapeutic potential.
Please note that only non-confidential information should be provided.
The information provided will be evaluated by Bayer scientific experts. The decision on amount of funding is dependent on the specific target and research plan proposed.
Successful applicants will be notified by Bayer and will receive further instructions concerning the grant. A Bayer caretaker will be in contact with you during the grant period.
To submit, you will be redirected to ScholarOne™ online submission platform. All the information provided has to be non-confidential to allow a first evaluation of the proposal.
Describe your idea and target, its characteristics (indication and treatment paradigm, the target´s druggability, and patent status).
Please indicate in the abstract if any particular data can only be disclosed under a Confidential Disclosure Agreement (CDA). In case your application is considered for further evaluation, we may contact you to discuss a CDA.
To assist in the grant allocation, the proposal should include a detailed description of the target proposed, the phase of discovery, and further research plans.
This information can be provided as PDF-Documents which can be attached to the application.
These supplements are to assist the scientific reviewers. The publications attached do not necessarily have to originate from yourself / your research group. Please attach the most relevant publications describing the target and its functional relevance for the indicated disease.
Bayer offers a unique incubator for startup life-science companies whose drug targets and technologies align with Bayer.s interests.
Bayer is promoting the exploration of new indications by offering grants and further financial support.
Bayer offers financial support to evaluate your antibody or derivate and to promote its exploration for a potential new drug development.